Join Our Newsletter
Get the best of VaccineNation in your inbox
Stay informed. Get the newsletter that gives you an edge in this rapidly changing sector, for free.
MOST POPULAR THIS MONTH
Access through innovation: Dr Carmen Ledesma-Feliciano
Our next conversation from the Congress last month is an interview with PharmaJet's Dr Carmen Ledesma-Feliciano. Dr Ledesma-Feliciano joined us for a presentation in the Bioprocessing and Manufacturing track. We were glad to sit down with her to discuss PharmaJet's...
Geo-diversification of vaccines: CEPI’s Dr Matthew Downham
Next in our interview series is CEPI's Dr Matthew Downham, who joined us at the Congress for a plenary session and a panel. We were excited to meet Dr Downham to get an insight into the work that CEPI is doing to encourage equitable access and establish sustainable...
Diseases are “not done with us”, says Dr Ofer Levy
Our next interviewee is Dr Ofer Levy of Boston Children's Hospital; he joined us in Washington for several different sessions to explore adjuvants and immune profiling. In this interview we continue our conversation from the Congress in Barcelona last year, learning...
Animal diseases are “red flags” says Professor James Roth
As part of our series of conversations with experts at the Congress in Washington last month we were lucky to meet Professor James Roth for an interview about his work on vaccines for transboundary diseases of livestock. He joined us at the Congress to discuss how...
Agricultural equilibrium: old meets new with Joel Harris
Our next interview guest from the Congress last month is Genvax Technologies' CEO and Co-Founder, Joel Harris. Joel joined us at the Congress for a presentation and a panel in the Veterinary track. We were glad to sit down with him to learn more about the approaches...
Dr Jules Millogo: “human beings want to do the right thing”
During the Congress in Washington last month we were lucky that Dr Jules Millogo made time to meet for a conversation about his work. He joined the event for two sessions, the first on Merck's Ebola experience and the second on supply chain technologies. It was a...
Galvanising the vaccine ecosystem: David Humphreys
Next up in our exclusive series of Congress interviews is this conversation with David Humphreys, Global Head of Health Policy at Economist Impact. David joined us for conversations about what we learnt from the COVID-19 pandemic, and a discussion on Economist...
Conducting challenge trials: hVIVO’s Dr Andrew Catchpole
Our next guest is Dr Andrew Catchpole, hVIVO's Chief Scientific Officer, who joined us in Washington for the Clinical Development and Trials track. Here we learn more about how hVIVO approaches challenge studies, and how beneficial these can be for efficient and...
